Overview

A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma

Status:
Terminated
Trial end date:
2008-05-01
Target enrollment:
0
Participant gender:
All
Summary
This study evaluated the efficacy and safety of Avastin (bevacizumab, 5 mg/kg intravenously every 2 weeks) in patients with multiple myeloma, relapsed/refractory after at least 2 lines of prior therapy.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Bevacizumab
Criteria
Inclusion Criteria:

- Adult patients, 19-75 years of age

- Multiple myeloma.

- Progressive disease after at least 2 lines of prior therapy.

Exclusion Criteria:

- Non-secretory myeloma.

- History of malignancy, other than squamous cell cancer, basal cell cancer, or cancer
in situ of the cervix within the last 5 years.

- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to study treatment start.

- Clinically significant cardiac disease.